NCT07835971

Brief Summary

The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
319

participants targeted

Target at P75+ for phase_2 hypertension

Timeline
Completed

Started Dec 2025

Shorter than P25 for phase_2 hypertension

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 24, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2026

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 17, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 23, 2026

Completed
Last Updated

September 23, 2026

Status Verified

September 1, 2026

Enrollment Period

9 months

First QC Date

September 17, 2026

Last Update Submit

September 17, 2026

Conditions

Hypertension

Keywords

HypertensionsiRNAGW906SAL0132

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in mean sitting systolic blood pressure (msSBP) at Week 12

    msSBP will be measured in the office using a validated sphygmomanometer, with the participant seated and resting quietly for at least 5 minutes. The primary endpoint is the change from baseline, calculated as the Week 12 value minus the baseline value, expressed in mmHg

    Baseline and Month 3

Secondary Outcomes (1)

  • Change from baseline in mean sitting systolic blood pressure (msSBP) at Weeks 4, 8, and 24 of the double-blind period

    Baseline, Weeks 4, 8, and 24

Study Arms (2)

GW906

EXPERIMENTAL

Subcutaneous injection

Drug: GW906

Placebo

PLACEBO COMPARATOR

Subcutaneous injection

Drug: Placebo

Interventions

GW906DRUG

Subcutaneous injection

GW906
PlaceboDRUG

Subcutaneous injection

Placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years and ≤ 75 years, of either sex.
  • Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and \< 180 mmHg at screening.
  • Willing to participate in the study and provide written informed consent.

You may not qualify if:

  • Secondary hypertension.
  • orthostatic hypotension.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2.
  • Received an investigational agent within the last 3 months.
  • Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus.
  • History of any cardiovascular event within 12 months.
  • History of intolerance to SC injection(s).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China

Shanghai, Shanghai Municipality, 200025, China

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2026

First Posted

September 23, 2026

Study Start

December 24, 2025

Primary Completion

September 15, 2026

Study Completion

September 15, 2026

Last Updated

September 23, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)